Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Iglu Sugar Free Pastilles

Active Ingredient:
benzalkonium chloride solution , compound benzoin tincture
Company:  
Diomed Developments Limited See contact details
About Medicine
{medical_services}
General Sales List
Healthcare Professionals (SmPC) Patient Leaflet (PIL) HCP Med Info
{arrow_left}
{arrow_right}
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 10 Dec 2020

Quick Links

Undesirable Effects Pharmacological Properties Interactions Posology Contraindications Excipients Storage precautions
{printer} Print SmPC information
1. Name of the medicinal product

Iglu Sugar Free Pastilles

2. Qualitative and quantitative composition

Benzalkonium Chloride Solution 1.11 mg per pastille

Compound Benzoin Tincture 8.06 mg per pastille (0.75% v/w)

Excipient(s) with known effect

Sorbitol liquid 363.3 mg per pastille

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Pastille

4. Clinical particulars
4.1 Therapeutic indications

For the relief of mouth ulcers and sore gums

4.2 Posology and method of administration

Adults, the elderly and children of 3 years and above: Dissolve one pastille in the mouth at 2 hourly intervals.

Do not take more than 8 pastilles per day.

4.3 Contraindications

Hypersensitivity to benzalkonium chloride, benzoin or any of the other ingredients.

Contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this medicine.

4.4 Special warnings and precautions for use

None

4.5 Interaction with other medicinal products and other forms of interaction

None known

4.6 Fertility, pregnancy and lactation

Pregnancy

There is no or inadequate evidence of the safety of the active ingredients in this medicine in human pregnancy. The potential risk for humans is unknown.

In the absence of sufficient data, the use during pregnancy is not recommended.

Lactation

It is not known whether the active ingredients of this product are excreted in human breast milk.

In the absence of sufficient data, the use during lactation is not recommended.

Fertility

Studies of the effects on fertility have not been investigated

4.7 Effects on ability to drive and use machines

None known

4.8 Undesirable effects

Sensitivity to benzalkonium chloride may occur in some people.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

4.9 Overdose

Symptoms of overdose are unlikely unless the recommended dosage is grossly exceeded, when nausea and vomiting may be seen. Treat by discontinuation, giving milk and egg whites and observation.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Benzalkonium chloride is an antiseptic detergent.

Benzoin tincture is included as a mild antiseptic and a mucosal protective.

5.2 Pharmacokinetic properties

The product is used by being allowed to dissolve in the mouth, and its action is therefore dependent on local distribution in the buccal cavity and contact with the affected areas.

5.3 Preclinical safety data

None specific to the product.

6. Pharmaceutical particulars
6.1 List of excipients

Sorbitol liquid, non crystallising

Acacia

Peppermint Oil

Simethicone Antifoam (water, polydimethyl siloxane and silica mix, polyoxyethylene 20 sorbitan monostearate, glyceryl monostearate, sodium carboxymethyl cellulose, methyl-4-hydroxybenzoate, propyl-4-hydroxybenzoate, hydrogen chloride)

Vegetable oil

Carnauba wax

Water

6.2 Incompatibilities

None known

6.3 Shelf life

36 months

6.4 Special precautions for storage

Do not store above 25° C. Store in the original package in order to protect from moisture.

6.5 Nature and contents of container

24 pastilles, blister packed and contained in a printed carton

45 g pastilles contained in a laminate bag integral with a printed carton.

6.6 Special precautions for disposal and other handling

None specific to packs

7. Marketing authorisation holder

Ernest Jackson & Co Ltd

High Street

Crediton

Devon EX17 3AP

UK

8. Marketing authorisation number(s)

PL 00094/5016R

9. Date of first authorisation/renewal of the authorisation

11/10/1989 / 01/05/08

10. Date of revision of the text

13/11/2020

Diomed Developments Limited
Company image
Address
Tatmore Place, Gosmore, Hitchin, Herts, SG4 7QR
Telephone
+44 (0)1462 458 866
WWW
www.diomedgroup.co.uk